Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. - Wikidata - wikimedia - TriplyDB

Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

http://www.wikidata.org/entity/Q42558314

about

Epigenetic susceptibility factors for prostate cancer with aging.Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer Methylation of the RARB gene increases prostate cancer risk in black Americans Emerging drugs for prostate cancer.Prognostic DNA methylation markers for prostate cancer.The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.Addressing the need for repeat prostate biopsy: new technology and approaches.Risk stratification of prostate cancer 2016.Morbidity and psychological impact of prostate biopsy: the future calls for a change.Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer.Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients.Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer.

P2860

Q34541756-41484EFE-E42F-4F6A-BFA3-44E19C8AF145 Q36730582-40CC00F5-4C13-4C8A-9B64-F8CA1D8BFD69 Q37187963-2A8C4A28-CE00-4261-AE1B-FC4D892EB103 Q38166018-7D1649B3-16DA-402B-9B68-2567DE31FD5F Q38252624-EA99C73D-C891-4617-BD5F-1486B4C7631F Q38269155-BC9E63E7-D319-4711-8C4C-02C8594CBBCA Q38356863-26926A3E-0AA7-473D-85B1-7BC748661E69 Q38392009-A0F3CD00-5BFD-4605-B1A9-5C28550B1F4F Q38546671-90E8480F-C560-471F-8DCC-725DA88796AC Q38929868-C411E363-0C5D-4EFE-B7D3-CDFA5EC02B18 Q39213491-770B9FE2-3C5F-4EBF-90ED-BFD45C417744 Q40920100-0E73254A-672C-43A9-9F8B-E16652B9057B Q42256326-90173EB7-BFED-41B1-9F7F-FC569BDD2F12 Q43083508-64554E24-6167-4701-8DC6-CCFCD9986232 Q47141373-A9C4146E-4FA4-4D95-87BD-AAB590AF767E

P2860

Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

http://www.wikidata.org/entity/Q42558314

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

@en

Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

@nl

type

label

Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

@en

Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

@nl

prefLabel

Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

@en

Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

@nl

P1433

Q42558314-B6847412-2250-4125-B320-CAFB348A712D

P1476

Q42558314-3CBD6583-3010-4CE6-95D3-479498D94DF2

P2093

Q42558314-0AB81D8F-80F5-4A8D-8042-8F0FE5C71B9D

Q42558314-13FEB1FD-4C5B-490F-A73E-2EA4C609FE56

Q42558314-6FF4A17C-D8EF-4A5E-BB0A-D0F1339A925B

Q42558314-7326E1C3-E6CF-404C-B3FE-1AD4B2B5A85B

Q42558314-8D7A0B68-59F6-4953-A637-0817C2EF150C

Q42558314-94303C34-A50A-40BE-94E3-33875F1CB28E

Q42558314-B37D963E-0C0B-450A-AE72-8A23E33D94D8

Q42558314-C83798BE-4F1D-4234-8A9B-606262EF81DB

Q42558314-DAF7E465-1651-41F6-976B-D6EAC723A1E7

Q42558314-F00DB4FA-DA47-48A3-ADF8-B9F4B5569EA4

P2860

Q42558314-0029A45A-3336-42A2-AD81-D162C4DDB6D9

Q42558314-03217C79-2477-4F9D-9D58-BF85AA2A129E

Q42558314-06DB5A6E-9737-4751-990C-91A4D1896251

Q42558314-0977CED4-0006-42A3-932F-96DC1B544D40

Q42558314-0D11CA09-7845-41D7-BD0A-64704D326FA1

Q42558314-10219EBA-12E8-4A6B-B67D-C9BF360E2698

Q42558314-18F98C61-C7BC-4476-A789-DB032BF2E7C6

Q42558314-22C4465B-DC82-403D-9881-D51832B3E76B

Q42558314-322E7929-DC45-41BA-8EDD-BA0AD2A29DA7

Q42558314-34FFACF2-B10C-4B22-A5C5-D51B47DDAE16

P304

Q42558314-91F16689-9637-4011-A557-5E30ADE1393B

P31

Q42558314-5C9A9FA3-85FC-44EA-BCC6-6B558522443E

P356

Q42558314-93EA5F72-988F-4770-ADC9-13A60201FBA4

P407

Q42558314-3412CF2B-537F-4CE4-BCE5-23F6BB439AD0

P433

Q42558314-6B326E13-12E2-4EAA-936E-2BC0DA1C90DC

P478

Q42558314-C68AE258-EDB0-4A61-8743-E8A3CC224BC1

P577

Q42558314-359F43E3-0858-4383-B5C5-2D0C8BE416F9

P5875

Q42558314-A52C00CA-8968-4B0C-ABE7-AF87F8609175

P698

Q42558314-15DECEF5-14E8-4417-8693-3DD3CB51B9E5

P932

Q42558314-EEF05CA2-0D59-43FC-91F6-32DDE9B8E1A6

P356

J.JURO.2012.11.074

P1433

The Journal of Urology

P1476

Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.

@en

P2093

Andrew Livermore

http://www.w3.org/2001/XMLSchema#string

Bing Yang

http://www.w3.org/2001/XMLSchema#string

Daniel W Lin

http://www.w3.org/2001/XMLSchema#string

David F Jarrard

http://www.w3.org/2001/XMLSchema#string

Jennifer Wagner

http://www.w3.org/2001/XMLSchema#string

Joel Nelson

http://www.w3.org/2001/XMLSchema#string

Matthew Truong

http://www.w3.org/2001/XMLSchema#string

Puspha Weeratunga

http://www.w3.org/2001/XMLSchema#string

Rajiv Dhir

http://www.w3.org/2001/XMLSchema#string

Wei Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Fibroblast growth factor signalling: from development to cancer

Hypermethylation of the caveolin-1 gene promoter in prostate cancer.

Molecular evidence supporting field effect in urothelial carcinogenesis.

RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues.

Clinical implications and utility of field cancerization

Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect.

Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Evidence for field cancerization of the prostate.

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.

P304

2335-2341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2012.11.074

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

189

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233536952

http://www.w3.org/2001/XMLSchema#string

P698

23159584

http://www.w3.org/2001/XMLSchema#string

P932

4226217

http://www.w3.org/2001/XMLSchema#string